17-31163376-G-A
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PM5PP2PP3PP5_Very_Strong
The ENST00000358273.9(NF1):c.479G>A(p.Arg160Lys) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R160S) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000358273.9 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NF1 | NM_001042492.3 | c.479G>A | p.Arg160Lys | missense_variant, splice_region_variant | 4/58 | ENST00000358273.9 | NP_001035957.1 | |
NF1 | NM_000267.3 | c.479G>A | p.Arg160Lys | missense_variant, splice_region_variant | 4/57 | NP_000258.1 | ||
NF1 | NM_001128147.3 | c.479G>A | p.Arg160Lys | missense_variant, splice_region_variant | 4/15 | NP_001121619.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NF1 | ENST00000358273.9 | c.479G>A | p.Arg160Lys | missense_variant, splice_region_variant | 4/58 | 1 | NM_001042492.3 | ENSP00000351015 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Neurofibromatosis, type 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | NHS Central & South Genomic Laboratory Hub | Nov 11, 2024 | - - |
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 26, 2017 | The c.479G>A variant (also known as p.R160K), located in coding exon 4 of the NF1 gene, results from a G to A substitution at nucleotide position 479. The amino acid change results in arginine to lysine at codon 160, an amino acid with highly similar properties. However, this change occurs in the last base pair of coding exon 4, which makes it likely to have some effect on normal mRNA splicing. This alteration was detected in one individual meeting clinical diagnostic criteria for neurofibromatosis type 1 (NF1) (Ambry internal data), as well as one individual from a prospective cohort of patients with clinical suspicion of NF1 (Pasmant E et al. Eur. J. Hum. Genet., 2015 May;23:596-601). A different nucleotide change at the same position (c.479G>C) has been identified in two individuals meeting NF1 clinical diagnostic criteria and was shown via mRNA analysis to result in exon-skipping (Wimmer K et al. Hum. Mutat., 2007 Jun;28:599-612; Ponti G et al. Hered Cancer Clin Pract, 2011 Aug;9:6). In addition, another different nucleotide change at the same position (c.479G>T) occurred de novo in an individual meeting NF1 diagnostic criteria (Bianchessi D et al. Mol Genet Genomic Med, 2015 Nov;3:513-25; Leiden Open Variation Database- http:// www.LOVD.nl/NF1). This nucleotide position is highly conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to weaken the efficiency of the native splice donor site; however, direct evidence is unavailable. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at